N/A N=300 Prevention

Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta

Liver Cancer

Bottom Line

View on ClinicalTrials.gov: NCT02461966 ↗

Enrolled (actual)

300

Serious AEs

0.0%

Results posted

Oct 2017

Primary outcome: Primary: Serum Aflatoxin Level in Liver Cancer Patients — 7.96; 6.10; 4.13 ng\ml

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Aflatoxin (Other)
Age: Pediatric, Adult, Older Adult
Sex: All
Sponsor: Sherief Abd-Elsalam
Primary completion: Apr 2016

Outcome Measures

Outcome	Result	p-value
PRIMARY Serum Aflatoxin Level in Liver Cancer Patients	7.96; 6.10; 4.13	—

Summary

Hepatocellular carcinoma is multifactorial in etiology and complex in pathogenesis, the blend of risk factors differs in different parts of the world, and this may explain in part the diverse biologic characteristics of HCC in different populations . Exposure to aflatoxin is an additional risk factor for the development of HCC, through damage of DNA in liver cells and mutation in p53 tumor suppressor gene . A previous study showed that aflatoxin B1 has a considerable role in the development of HCC among Egyptians . Clinical studies have shown that AFB1 selectively targets at the third base position of codon 249 of the human p53 gene, a known mutational hotspot in human hepatocellular carcinoma (HCC) . A significant association between aflatoxin exposure and HCC has been reported in hyperendemic areas . A synergistic interaction between AFB1 exposure and viral hepatitis B (HBV) infection on HCC risk has been reported in several epidemiologic studies. Aflatoxin exposure may be associated with advanced liver disease in chronic hepatitis C (HCV) patients. Levels of AFB1-albumin/albumin were significantly related to ultrasono-graphic hepatic parenchyma scores in anti-HCV-positive subjects .

Eligibility Criteria

Inclusion Criteria

cirrhotic patient with and without HCC

Exclusion Criteria

Malignancy other than HCC

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02461966). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.